An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
2020-07-04
عنوان الدراسة
An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
داعم الدراسة
Synageva
دواء الدراسة
Sebelipase alfa (SBC-102)
رقم بروتوكول الدراسة
LAL-CL03
حالة الدراسة
Completed
موقع الدراسة
King Faisal Specialist Hospital and Research Center (Riyadh)
مرحلة الدراسة
2
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。